- Home
- EHAB vs ZJYL Comparison
EHAB vs ZJYL Comparison
Compare EHAB & ZJYL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EHAB
- ZJYL
- Stock Information
- Founded
- EHAB 2014
- ZJYL 2006
- Country
- EHAB United States
- ZJYL China
- Employees
- EHAB N/A
- ZJYL N/A
- Industry
- EHAB Hospital/Nursing Management
- ZJYL Industrial Specialties
- Sector
- EHAB Health Care
- ZJYL Consumer Discretionary
- Exchange
- EHAB Nasdaq
- ZJYL Nasdaq
- Market Cap
- EHAB 401.6M
- ZJYL N/A
- IPO Year
- EHAB N/A
- ZJYL 2023
- Fundamental
- Price
- EHAB $7.06
- ZJYL $0.60
- Analyst Decision
- EHAB Buy
- ZJYL
- Analyst Count
- EHAB 2
- ZJYL 0
- Target Price
- EHAB $8.75
- ZJYL N/A
- AVG Volume (30 Days)
- EHAB 805.7K
- ZJYL 168.4K
- Earning Date
- EHAB 08-05-2025
- ZJYL 07-25-2025
- Dividend Yield
- EHAB N/A
- ZJYL N/A
- EPS Growth
- EHAB N/A
- ZJYL 18.46
- EPS
- EHAB N/A
- ZJYL 0.02
- Revenue
- EHAB $1,032,300,000.00
- ZJYL $23,502,010.00
- Revenue This Year
- EHAB $4.66
- ZJYL N/A
- Revenue Next Year
- EHAB $4.99
- ZJYL N/A
- P/E Ratio
- EHAB N/A
- ZJYL $25.86
- Revenue Growth
- EHAB N/A
- ZJYL 18.57
- 52 Week Low
- EHAB $6.85
- ZJYL $0.50
- 52 Week High
- EHAB $10.91
- ZJYL $4.38
- Technical
- Relative Strength Index (RSI)
- EHAB 21.36
- ZJYL 39.96
- Support Level
- EHAB $7.07
- ZJYL $0.50
- Resistance Level
- EHAB $7.54
- ZJYL $0.67
- Average True Range (ATR)
- EHAB 0.36
- ZJYL 0.06
- MACD
- EHAB -0.21
- ZJYL -0.00
- Stochastic Oscillator
- EHAB 3.84
- ZJYL 54.71
About EHAB Enhabit Inc.
Enhabit Inc provides home health and hospice services in the United States. Its reportable segments are Home Health and Hospice. The Home Health segment includes a comprehensive range of Medicare-certified home nursing services to adult patients in need of care. These services include, among others, skilled nursing, physical, occupational, and speech therapy, medical social work, and home health aide services. The Hospice segment focuses on the quality of life for patients who are experiencing an advanced, life-limiting illness while treating the person and symptoms of the disease, rather than the disease itself. The company generates a majority of its revenue from the Home Health segment.